Empagliflozin (JARDIANCE®) is proven to go beyond lowering A1C to reduce the risk of CV death for adults who have type 2 diabetes and heart disease

Empagliflozin (JARDIANCE^®) is proven to go beyond lowering A1C to reduce the risk of CV death for adults who have type 2 diabetes and heart disease

Metabolism_Jardiance_EMPEROR-Preserved expert opinion and summary video_15-7-22

Document ID: PC-PH-103973

11/08/2022

Author: Boehringer Ingelheim

Related content